Homevideos Newshealthcare News

    Experts weigh in on COVID-19 opportunity in Indian pharma sector for 2022

    videos | IST

    Experts weigh in on COVID-19 opportunity in Indian pharma sector for 2022

    Mini

    Pharmaceutical sector has made a comeback after the profit taking as worries on COVID-19 re-emerge. One of the biggest developments for pharmaceutical companies in 2021 was the second wave of COVID-19, which resulted in a huge spike in sales for many of the companies, only to ebb towards the end of the year. Vishal Manchanda, Pharma Analyst at Nirmal Bang Institutional Equities and Surajit Pal Pharma Analyst at BOBCAPS shared their perspectives.

    Pharmaceutical sector has made a comeback after the profit taking as worries on COVID-19 re-emerge. One of the biggest developments for pharmaceutical companies in 2021 was the second wave of COVID-19, which resulted in a huge spike in sales for many of the companies, only to ebb towards the end of the year. COVID-19 sales were majorly captured in Q1 India sales with many alluding to tapering. However, while sales from COVID-19 related drugs might have dwindled, it could remain an opportunity for 2022.
    Vishal Manchanda, Pharma Analyst at Nirmal Bang Institutional Equities and Surajit Pal Pharma Analyst at BOBCAPS shared their perspectives.
    For the full interview, watch the accompanying video.
    Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
    next story

      Most Read

      Market Movers

      View All
      CompanyPriceChng%Chng